Advise on IT / data platform strategy for the Energy Efficiency group.

IoT start-up focused on ensuring clean air for the next generation of residential customers.

Co-founder of a cleantech start-up developing a leading M2M/IoT platform. Leadership roles in all major activities, including finance, fund-raising, customer acquisition & retention, strategy, execution, supply chain management, technology R&D, and product design. Currently, CTO but filled CEO role for 7 years. - Successfully developed and launched hardware and software on a bootstrap using limited funds - Brought in seed- and growth-capital into the company through debt and equity financings- Experienced negotiator and closer of all types of partnerships (OEM, R&D, marketing) with global, market leading companies- Built up ThinkEco's IP portfolio from scratch- Key decision-maker on all aspects of ThinkEco's technology & business strategy- Lead inventor of patented ThinkEco technologies- Built a tight-knit, dedicated team committed to ThinkEco’s company goals

Theoretical biophysics research towards understanding the role of horizontal gene transfer in bacterial speciation events and neutral evolution - Bioinformatics analysis of publicly available genomic sequences - Development of a parallelized in silico simulation of bacterial evolution featuring replication, horizontal gene transfer events, and natural selection - Development of rigorous mathematical models of bacterial evolution based on modern condensed matter physics (spin glasses and branching processes)

Theoretical biophysics research into gene regulation and protein folding. Developed theory for understanding the evolution of DNA-binding proteins to maximize target site recognition efficiency. - Analysis of single-molecule traces of DNA binding proteins using modern diffusion physical theory and simulation. - Theoretical analysis of gel-based assay data on p53 diffusing on DNA. - Development of methods for engineering proteins so that they fold in a specific manner.

Analyzed financial equity performance for large cap and mid- to small-cap biotechnology companies. Performed due diligence in preparation for IPO or secondary stock offerings.

Was employee no. 5. Managed the R&D of novel lead discovery & optimization computational platform critical for the growth of this early stage company. Computational platform led to a technology partnership with an industry leading Fortune 25 company and a hypertension drug development partnership with a global top 5 pharmaceutical corporation. - Played an important role in private equity fund-raising and company strategy and as it grew from 5 to 60+ employees. - Participated in the decision-making process of structure-based inflammatory, CNS and hypertension lead discovery programs. - Invented and implemented parallelizable, computationally efficient methods for high-throughput fragment-based, combinatorial in silico growth of small molecules inhibitors - Created novel methods used to predict drug efficacy using concepts drawn from machine learning and statistical mechanics- Published 2 articles and 1 book chapter